Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 5, 1998, Pages 1636-1643

  Park, Kyong Soo ^b   Ciaraldi, Theodore P ^b   Abrams Carter, Leslie ^b   Mudaliar, Sunder ^b   Nikoulina, Svetlana E ^b   Henry, Robert R ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; GLUCOSE TRANSPORTER; GLYCOGEN SYNTHASE; INSULIN; METFORMIN; TROGLITAZONE;

ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN RESISTANCE; MUSCLE FIBER CULTURE; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

ADULT; CELLS, CULTURED; CHROMANS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOGEN SYNTHASE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE, SKELETAL; OBESITY; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES;

EID: 7844248273     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.5.1636     Document Type: Article

References (50)

1. DeFronzo RA, Bonadonna RC, Ferrannini E. 1992 Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 15:318-368.
2. Baron AD, Laasko M, Brechtel G, Edelman SV. 1991 Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in non-insulin dependent diabetic subjects. J Clin Invest. 87:1186-1194.
3. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. 1988 Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob / ob mice and Zucker fatty rats. Diabetes. 37:1549-1558.
4. Fujiwara T, Wada M, Fukuda K, et al. 1991 Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure in C57L/Ksj db/db mice. Metabolism. 40:1213-1218.
5. Iwamoto Y, Kuzuya T, Matsuda A, et al. 1991 Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1083-1086.
6. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky J. 1992 Metabolic effects of new oral hypoglycemic agents CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
7. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1188-1193.
8. Ciaraldi TP, Gilmore A, Olefsky JM, Golderg M, Heidenreich KA. 1996 In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 39:1056-1062.
9. Tafuri SR. 1996 Troglitazone enhances differentiation, basal glucose uptake, and GLUT1 protein levels in 3T3-L1 adipocytes. Endocrinology. 137:4706-4712.
10. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM. 1995 Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 44:976-982.
11. Bahr M, Spelleken M, Bock M, von Holtey M, Eckel J. 1996 Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes, Diabetologia. 39:766-774.
12. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP. 1995 Insulin action and glucose metabolism in non-diabetic control and NIDDM subjects: comparison using human skeletal muscle cell cultures. Diabetes. 44:936-946.
13. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE. 1996 Glycogen synthase activity is reduced in cultured skeletal muscle cells of NIDDM subjects: biochemical and molecular mechanisms. J Clin Invest. 98:1231-1236.
14. Ciaraldi T, Abrams L, Nikoulina S, Mudaliar S, Henry RR. 1995 Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects. J Clin Invest. 96:2820-2827.
15. Henry RR, Ciaraldi TP, Mudaliar S, Abrams L, Nikoulina S. 1996 Acquired defects of glycogen synthase activity in cultured human skeletal muscle cells: influence of high glucose and insulin levels. Diabetes. 45:400-407.
16. National Diabetes Data Group. 1979 Classification and diagnosis of diabetes mellitus and other categories of glucose tolerance. Diabetes. 28:1039-1057.
17. Blau HM, Webster C. 1981 Isolation and characterization of human muscle cells. Proc Natl Acad Sci USA. 78:5623-5627.
18. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A. 1990 Glucose uptake in human and animal muscle cells in culture. Biochem Cell Biol. 68:536-542.
19. Ailhaud G. 1982 Adipose cell differentiation in culture. Mol Cell Biochem. 49:17-31.
20. Klip A, Li G, Logan WJ. 1984 Induction of sugar uptake response to insulin by serum depletion in fusing L6 myoblast. Am J Physiol. 247:E291-E296.
21. Bradford MM. 1976 A rapid and sensitive method for the quantitation of protein utilizing the principle of protein-dye binding. Anal Biochem. 71:248-254.
22. Walker PS, Ramlal T, Sarabia V, et al. 1990 Glucose transport activity in L6 muscle cells is regulated by the cordinate control of subcellular glucose transporter distribution, biosynthesis, and mRNA transcription. J Biol Chem. 265:1516-1523.
23. Burnette WN. 1989 "Western blotting:" electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 112:195-203.
24. Wang AM, Doyle MV, Mark DF. 1989 Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA. 86:9717-9721.
25. Browner MF, Nakano K, Bang AG, Fletterick RF. 1989 Human muscle glycogen synthase cDNA sequence: a negatively charged protein with an asymmetric charge distribution. Proc Natl Acad Sci USA. 86:1443-1447.
26. Fukumoto H, Seino S, Imura H, Seino Y, Bell GI. 1988 Characterization and expression of human hepG2/erythrocyte glucose-transporter gene. Diabetes. 37:657-661.
27. Birnbaum MJ. 1989 Identification of a novel gene encoding an insulin-responsive glucose transporter protein. Cell. 57:305-315.
28. Hofmann C, Lerenz K, Colca JR. 1991 Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology. 129:1915-1925.
29. Stevenson RW, Hutson NJ, Krupp MN, et al. 1990 Actions of novel antidiabetic agent englitazone in hyperglycemic hvperinsulinemic ob/ob mice. Diabetes. 39:1218-1227.
30. Shargill NS, Tatoyan A, Fukishima M. 1986 Effect of ciglitazone on glucose uptake and insulin sensitivity in skeletal muscle of the obese (ob/ob) mouse: distinct insulin and glucocorticoid effects. Metabolism. 35:64-70.
31. Thorburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR. 1991 Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest. 87:489-495.
32. Horikoshi H, Okuno A, Fujiwara T, Shiota M, Sugano T. 1993 Peripheral effects of a new antidiabetic agent, CS-045: acute stimulation of insulin-induced glucose uptake in perfused rat hindlimb [Abstract 188]. Diabetes 42(Suppl 1):59A.
33. Lee M-K, Olefsky JM. 1995 Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism. 44:1166-1169.
34. Shibata H, Nii S, Kobayashi M, et al. 1993 Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers. Safety and pharmacokinetics in repeated administration. Rinsho lyaku. 9:1519-1537.
35. Weinstein SP, Holand A, O'Boyle E. 1993 Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism. 42:1365-1369.
36. Sandouk T, Rada D, Hofmann C. 1993 The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology. 133:352-359.
37. El-Kebbi I, Roser S, Pollet RJ. 1994 Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism. 43:953-958.
38. Mueckler M. 1944 Facilitative glucose transporters. Eur J Biochem. 219:713-725.
39. Ciaraldi TP, Mudaliar S, Henry RR. 1995 Relationship between skeletal muscle GLUT1/GLUT4 and glucose disposal [Abstract 567]. Diabetes 44(Suppl 1):165A.
40. Bak JK, Moller N, Schmitz O, Saaek A, Pedersen O. 1992 In vivo insulin action and muscle glycogen synthase activity in type II (non-insulin-dependent) diabetes mellitus: effects of diet treatment. Diabetologia. 35:777-784.
41. Lawrence Jr JC, Roach PJ. 1997 New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes. 46:541-547.
42. Kellerer M, Kroder G, Tippmer S, et al. 1994 Troglitazone prevents glucose-induced insulin resistance of insulin receptor in Rat-1 fibroblasts. Diabetes. 43:447-453.
43. Maegawa H, Ide R, Hasegawa M, et al. 1995 Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. J Biol Chem. 270:7724-7730.
44. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA. 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPARγ). J Biol Chem. 270: 12953-12956.
45. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR. 1997 PPARγ gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes. 46:1230-1234.
46. Park KS, Abrams-Carter L, Mudaliar S, Nikoulina S, Henry RR. 1997 Troglitazone effects on gene expression in human skeletal muscle involve regulation of PPARγ [Abstract 85]. Diabetes. 46(Suppl 1):22A.
47. Khoursheed M, Miles PD, Gao KM, Lee MK, Moossa AR, Olefsky JM. 1995 Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism. 44:1489-1494.
48. Lee M-K, Miles PDG, Khoursheed M, Gao K-M, Moossa AR, Olefsky JM. 1994 Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 43:1435-1439.
49. Yagi N, Takasu N, Higa S, Ishikawa K, Murakami K, Mimura G. 1995 Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. Horm Metab Res. 27:439-441.
50. Stevenson RW, McPherson RK, Persson LM, et al. 1996 The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet. Diabetes. 45:60-66.